Practical instructions on the price level, purchasing methods and authenticity identification of Canakinumab

Canakinumab (Canakinumab) is a humanized anti-IL-1β monoclonal antibody developed by Novartis. It is suitable for a variety of autoinflammatory diseases, including periodic fever syndrome (such as CAPS, TRAPS, FMF), systemic juvenile idiopathic arthritis and adult gout attacks. As of now, the drug has not been approved for marketing by the drug regulatory authorities in mainland China. If patients want to use it, they need to obtain it through overseas or personal import channels. This also puts forward higher requirements on price, drug purchase channels, and authenticity identification.

In terms of price,Canakinumab, as a biological agent for the treatment of rare diseases, is generally priced high globally. Especially in the absence of medical insurance support, the cost of treatment cannot be ignored. According to public information, in the U.S. market, the market price of a 150 mg/1.0 mL injection of canakinumab is approximately US$16,000 to US$18,000; in some European countries such as Germany and Switzerland, the price of the drug is usually between €12,000 and €15,000. Since the frequency of use is one injection every 4 to 8 weeks, the annual treatment cost may reach hundreds of thousands of yuan or more. Some international medical assistance programs or rare disease funds sometimes offer limited financial support, but have strict coverage and eligibility criteria.

Since it has not yet been approved in China, patients cannot purchase canakinumab through hospital pharmacies or formal e-commerce platforms. The more common ways of obtaining drugs include purchasing drugs directly after seeking medical treatment abroad, consulting overseas medical service institutions, or entrusting overseas relatives. When choosing an institution, patients must check its legal qualifications, source of supply and customer feedback.

In terms of authenticity identification, canakinumab, as an injectable drug transported in the cold chain, has higher requirements for storage conditions. The outer packaging of the original drug is usually a white carton with the words "Canakinumab 150mg/mL" printed on it, as well as the Novartis trademark, anti-counterfeiting code and batch number. Each medicine will be marked with production batch number, expiration date, production place and other information, and the multi-lingual printing on the packaging should be neat and standardized. After receiving the medicine, patients should verify whether the outer packaging is consistent with the original manufacturer's style. They can check the drug information through the Novartis official website, or call the local Novartis office to inquire about relevant anti-counterfeiting measures. During the purchase process, if you find abnormalities such as damaged packaging, unclear batch numbers, missing instructions, or no cold chain records during transportation, you should suspend use and verify the situation with the supplier.

In general, sinceCanakinumab has not yet been launched in China, is expensive and has limited drug purchase channels, patients should fully weigh the efficacy, economic burden and accessibility before deciding to use it. It is recommended to complete the prescription evaluation under the guidance of experienced professional doctors, and to choose formal and transparent ways to obtain drugs as much as possible to ensure drug safety and therapeutic effect.

Reference materials:https://www.drugs.com/search.php?searchterm=ILARIS&sources%5B%5D=professional